Adder Envenomation in the UK: Epidemiology, Antivenom Need and Recombinant Therapeutic Development
Supervisors:
Dr Stefanie Menzies, Biomedical and Life Sciences, Lancaster University
Prof Willie Weir, University of Glasgow
Dr Nick Robinson, Lancaster University
Summary:
Adder (Vipera berus) envenomation is an important veterinary problem in the UK, but its true incidence and geographical distribution are poorly defined. This PhD will combine veterinary epidemiology with recombinant antibody development to better understand where adder bites occur and to develop a future canine-specific antivenom.
Working with veterinary networks in Scotland and North West England, the student will survey suspected and confirmed adder bites in companion animals and livestock, map cases against known adder habitat, and assess patterns of antivenom use and access. This will help identify regional treatment needs and potential gaps in antivenom provision.
In parallel, the student will develop a monoclonal antibody against a Vipera berus toxin (phospholipase A₂). A human scFv yeast-display library will be screened to identify neutralising antibodies, which will then be engineered into canine-compatible IgGs and evaluated in vitro and in vivo.
The student will gain broad training in veterinary epidemiology, spatial data analysis, recombinant protein production, antibody discovery, protein engineering, biochemical assays and preclinical study design. They will also develop transferable skills in data analysis, scientific writing, stakeholder engagement, research communication and translational planning, preparing them for careers across biotechnology, veterinary medicine, pharmaceutical development, epidemiology and academia.